4DMedical's Research Agreement with U.S. Dept of Veteran Affairs

4DMedical Limited (ASX: $4DX) has announced the signing of a research agreement with the U.S. Department of Veterans Affairs (VA) through its subsidiary, Imbio. The project will utilize Imbio's Lung Texture Analysis (LTA) to retrospectively assess the CT scans of a cohort of Veterans who underwent Lung Cancer Screening (LCS) between 2014 and 2017 to determine the prevalence, diagnostic delay, and mortality associated with interstitial lung abnormalities (ILA) and interstitial lung disease (ILD).

Executive Commentary on Research Agreement

4DMedical's transformational acquisition of Imbio is already yielding results with an additional pathway to supporting lung health in the Veteran community. This research agreement is a major milestone in adding value to lung cancer screening programs in the VA and elsewhere, as we progress our LTA product to FDA approval later this year. 4DMedical's demonstrated work to date with Veterans has been focused on exposures to airborne hazards during deployment and look forward to sharing further progress on this over the coming weeks and months.

Summary of 4DMedical's Research Agreement

4DMedical Limited (ASX: $4DX) has secured a research agreement with the U.S. Department of Veterans Affairs (VA) through its subsidiary, Imbio, to utilize Imbio's Lung Texture Analysis (LTA) for assessing the CT scans of Veterans who underwent Lung Cancer Screening (LCS) to determine the prevalence of interstitial lung abnormalities (ILA) and interstitial lung disease (ILD). The project aims to quantify the delay between acquisition of the lung cancer screening CT and diagnosis of pulmonary fibrosis, and to extract additional baseline demographic, comorbidity, and 5-year outcome data from the electronic health record. This initiative reflects 4DMedical's commitment to advancing respiratory imaging technology and its dedication to improving the early diagnosis and care of lung-related conditions in the Veteran community.